

	Description of Recommendation	P & T Vote
6	<p><u>New Products to Market: Ampyra®</u> Allow Ampyra® to pay with a diagnosis of MS (ICD-9 = 340) for an initial 12 weeks of therapy. After the initial 12 weeks of therapy, allow continuation of Ampyra® therapy if the drug has shown clinical efficacy. Additionally, this drug should have a quantity limit of 20 mg per day.</p>	<p>Passed 11 For 0 Against</p>
7	<p><u>New Products to Market: Cayston®</u> Allow Cayston® to pay if one of the following is true:</p> <ul style="list-style-type: none"> • Trial and failure of tobramycin (TOBI®); OR • Documented <i>P. aeruginosa</i> of the lungs that is resistant to tobramycin (TOBI®). 	<p>Passed 11 For 0 Against</p>
8	<p><u>Thrombopoiesis Stimulating Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one product indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and one product indicated for the prevention of severe thrombocytopenia and the reduction of platelet transfusions following myelosuppressive chemotherapy should be preferred. 2. All agents in this class should require PA to ensure appropriate utilization. 3. For any new chemical entity in the Thrombopoiesis Stimulating Agents class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 1 Against</p>
9	<p><u>Thrombopoiesis Stimulating Agents Clinical Criteria</u></p> <ul style="list-style-type: none"> ▪ Promacta® and Nplate™ will be approved for a diagnosis of chronic immune (idiopathic) thrombocytopenic purpura (ITP). ▪ Neumega® will be approved for a diagnosis severe thrombocytopenia following myelosuppressive chemotherapy. 	<p>Passed 9 For 2 Against</p>
10	<p><u>Topical Steroids</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one agent in each of the potency categories (low, medium, high and very high) should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Topical Steroids class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>

	Description of Recommendation	P & T Vote
11	<p><u>Ophthalmic Direct Acting Miotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Glaucoma Direct Acting Miotics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
12	<p><u>Ophthalmic Sympathomimetics</u></p> <ol style="list-style-type: none"> 1. Combine the PDL categories Ophthalmic Alpha-2 Agonists and Ophthalmic Sympathomimetics into one PDL category titled Ophthalmic Sympathomimetics. 2. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 3. Agents not selected as preferred will be considered non preferred and require PA. 4. For any new chemical entity in the Ophthalmic Sympathomimetics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
13	<p><u>Ophthalmic Beta Blockers</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least three unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Beta Blockers class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
14	<p><u>Ophthalmic Carbonic Anhydrase Inhibitors</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Carbonic Anhydrase Inhibitors class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
15	<p><u>Ophthalmic Antibiotics, Non-Quinolones</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least three unique chemical entities and two combination products containing a steroid should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Antibiotics, Non-Quinolones class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>

	Description of Recommendation	P & T Vote
16	<p><u>Ophthalmic Antivirals</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Antivirals class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
17	<p><u>Ophthalmic Antifungals</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Antifungals class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
18	<p><u>Ophthalmic Antihistamines</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Antihistamines class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
19	<p><u>Ophthalmic Mast Cell Stabilizers</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Mast Cell Stabilizers class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
20	<p><u>Ophthalmic NSAIDs</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic NSAIDs class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
21	<p><u>Ophthalmic Anti-Inflammatory Steroids</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least three unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Anti-inflammatory Steroids class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>

	Description of Recommendation	P & T Vote
22	<p><u>Ophthalmic Decongestants</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Decongestants class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
23	<p><u>Ophthalmic Mydriatics & Mydriatic Combos</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities, one of which should be atropine, should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Mydriatics & Mydriatic Combos class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
24	<p><u>Ophthalmic Immunomodulators</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Ophthalmic Immunomodulator class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
25	<p><u>Proton Pump Inhibitors</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two agents should be preferred. 2. At least SoluTabs or one liquid formulation should be available for patients under the age of 12. 3. Continue current quantity limits on all agents in this class. 4. Agents not selected as preferred will be considered non preferred and require PA. 5. For any new chemical entity in the Proton Pump Inhibitors class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
26	<p><u>Otic Quinolone Antibiotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one single entity agent and one combination agent should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Otic: Quinolone Antibiotics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>

	Description of Recommendation	P & T Vote
27	<p><u>Otic Steroid and Antibiotic Combinations</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one agent should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Otic: Steroid and Antibiotic Combination class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
28	<p><u>Otic Miscellaneous</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least three unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Otic Miscellaneous class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
29	<p><u>Alpha Blockers for BPH</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two agents, one of which should be highly selective for the alpha receptors in the genitourinary tract, should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Alpha Blockers for BPH class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
30	<p><u>Androgen Hormone Inhibitors</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one agent should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Androgen Hormone Inhibitors class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>
31	<p><u>Androgen Hormone Inhibitors Clinical Criteria</u></p> <p>Androgen Hormone Inhibitors will be approved for a diagnosis of benign prostatic hyperplasia (BPH) via an ICD-9 override.</p>	<p>Passed</p> <p>11 For 0 Against</p>
32	<p><u>Electrolyte Depleters</u></p> <ol style="list-style-type: none"> 1. Rename this category Phosphate Binders. 2. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities, one of which should be a calcium based and a non-calcium based phosphate binder, should be preferred. 3. Agents not selected as preferred will be considered non preferred and require PA. 4. For any new chemical entity in the Electrolyte Depleters class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed</p> <p>11 For 0 Against</p>

	Description of Recommendation	P & T Vote
33	<p><u>Urinary Tract Antispasmodics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. One should be liquid oxybutynin IR and the other should be EITHER darifenacin OR fesoterodine ER. 2. Only patients who are unable to swallow or tolerate oral medications should be approved for non-oral formulations of agents in this class. 3. Continue current quantity limits on all agents in this class. 4. Agents not selected as preferred will be considered non preferred and require PA. 5. For any new chemical entity in the Urinary Tract Antispasmodic Class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 11 For 0 Against</p>
34	<p><u>Dermatologics: Antivirals</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Dermatologics: Antivirals class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>
35	<p><u>Dermatologics: Antiseborrheic Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Dermatologics: Antiseborrheic class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>
36	<p><u>Dermatologics: Antibiotic Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least two unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require PA. 3. For any new chemical entity in the Dermatologics Antibiotics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Passed 10 For 0 Against</p>